Skip to main content
Login
Contact
Subscribe
Search form
Search
The Decatur Daily Democrat
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Photos
Videos
Games
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Rigel Pharmaceuticals
(NQ:
RIGL
)
3.260
USD
-0.060 (-1.81%)
Official Closing Price
Updated: 5:57 PM EDT, Apr 9, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Rigel Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Rigel Announces Closing of Strategic Collaboration with Lilly
April 07, 2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the...
From
PR Newswire
Thinking about buying stock in Rigel Pharmaceuticals, AMC Entertainment, Vir Biotechnology, Oncolytics Biotech, or Senseonics Holdings?
March 12, 2021
InvestorsObserver issues critical PriceWatch Alerts for RIGL, AMC, VIR, ONCY, and SENS.
From
PR Newswire
Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients
March 11, 2021
Topline data expected in April 2021
From
PR Newswire
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 02, 2021
- Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million
From
PR Newswire
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update
February 23, 2021
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2020 financial results after market close on Tuesday, March 2, 2021. Rigel senior...
From
PR Newswire
Thinking about buying stock in Avinger, Rigel Pharmaceuticals, Vistagen Therapeutics, Bio-Path, or Corvus Pharmaceuticals?
February 18, 2021
InvestorsObserver issues critical PriceWatch Alerts for AVGR, RIGL, VTGN, BPTH, and CRVS.
From
PR Newswire
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
February 18, 2021
- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications
From
PR Newswire
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
January 29, 2021
Study has the potential to facilitate a filing for Emergency Use Authorization (EUA)
From
PR Newswire
Rigel Pharmaceuticals Provides Business Update
January 11, 2021
TAVALISSE® preliminary 2020 net product sales of approximately $61.7 million, a year-over-year increase of 41%
From
PR Newswire
Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 39th Annual J.P....
From
PR Newswire
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
December 17, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
December 17, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
December 04, 2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American...
From
PR Newswire
Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
November 23, 2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submission (NDS) for TAVALISSE® (fostamatinib disodium hexahydrate)...
From
PR Newswire
Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
November 17, 2020
FDA agrees to the proposed primary efficacy endpoint and additional secondary endpoints
From
PR Newswire
Rigel to Present at the Jefferies Virtual London Healthcare Conference
November 10, 2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual...
From
PR Newswire
Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update
November 05, 2020
Third quarter total revenues of $18.4 million
From
PR Newswire
Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update
October 29, 2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2020 financial results after market close on Thursday, November 5, 2020. Rigel senior management will...
From
PR Newswire
Thinking about buying stock in Just Energy, Extreme Networks, Aurora Cannabis, AcelRx Pharmaceuticals, or Rigel Pharmaceuticals?
October 09, 2020
InvestorsObserver issues critical PriceWatch Alerts for JE, EXTR, ACB, ACRX, and RIGL.
From
PR Newswire
Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
October 09, 2020
Trial being conducted at NIH Clinical Center in Bethesda, Maryland and Inova Fairfax Hospital in Virginia
From
PR Newswire
Thinking about buying stock in Northern Dynasty Minerals, Checkpoint Therapeutics, Rigel Pharmaceuticals, Vaxart, or Aytu Bioscience?
September 17, 2020
InvestorsObserver issues critical PriceWatch Alerts for NAK, CKPT, RIGL, VXRT, and AYTU.
From
PR Newswire
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
September 17, 2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the...
From
PR Newswire
Rigel to Present at Two Upcoming Investor Conferences
September 09, 2020
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at two virtual investor conferences in...
From
PR Newswire
Rigel to Participate in Citi's 15th Annual BioPharma Virtual Conference
September 02, 2020
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to participate in a panel discussion on COVID-19 during...
From
PR Newswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 21, 2020
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of...
From
PR Newswire
Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program
August 04, 2020
Second quarter net product sales of $15.0 million, a year-over-year increase of 47%
From
PR Newswire
Rigel Announces Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Business Update
July 28, 2020
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2020 financial results after market close on Tuesday, August 4, 2020. Rigel senior management will...
From
PR Newswire
Rigel Announces Post-hoc Data Analysis of TAVALISSE® in Adult Patients with Immune Thrombocytopenia Published in the British Journal of Haematology
July 27, 2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that a paper presenting a post-hoc data analysis of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, as well as accompanying...
From
PR Newswire
Thinking about buying stock in Moleculin Biotech, VBI Vaccines, Rigel Pharmaceuticals, Delta Air Lines, or Vivint Solar?
July 15, 2020
InvestorsObserver issues critical PriceWatch Alerts for MBRX, VBIV, RIGL, DAL, and VSLR.
From
PR Newswire
Clinical Trials for Evolving Targeted Therapies Fueling Gains for Brain Tumor Therapeutics Market
July 15, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.